HRP20211802T1 - Pripravak za kontroliranu stimulaciju jajnika - Google Patents
Pripravak za kontroliranu stimulaciju jajnika Download PDFInfo
- Publication number
- HRP20211802T1 HRP20211802T1 HRP20211802TT HRP20211802T HRP20211802T1 HR P20211802 T1 HRP20211802 T1 HR P20211802T1 HR P20211802T T HRP20211802T T HR P20211802TT HR P20211802 T HRP20211802 T HR P20211802T HR P20211802 T1 HRP20211802 T1 HR P20211802T1
- Authority
- HR
- Croatia
- Prior art keywords
- amh
- patient
- pmol
- body weight
- treatment
- Prior art date
Links
- 230000002611 ovarian Effects 0.000 title 1
- 230000000638 stimulation Effects 0.000 title 1
- 230000037396 body weight Effects 0.000 claims 10
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 claims 9
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 claims 9
- 229940028334 follicle stimulating hormone Drugs 0.000 claims 9
- 208000000509 infertility Diseases 0.000 claims 6
- 230000036512 infertility Effects 0.000 claims 6
- 231100000535 infertility Toxicity 0.000 claims 6
- 210000002966 serum Anatomy 0.000 claims 5
- 229940079593 drug Drugs 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Reproductive Health (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Food Science & Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (12)
1. Pripravak za uporabu u liječenju neplodnosti u azijskog pacijenta koji ima AMH ≥ 26 pmol/L i tjelesnu težinu < 52 kg, pri čemu pripravak sadrži dnevnu dozu od 6 do 8 µg rekombinantnog FSH.
2. Pripravak za uporabu u liječenju neplodnosti u azijskog pacijenta koji ima AMH ≥ 15 pmol/L i tjelesnu težinu < 60 kg, pri čemu pripravak sadrži dnevnu dozu od 6 do 8 µg rekombinantnog FSH.
3. Pripravak za uporabu prema patentnom zahtjevu 1 ili 2, naznačen time što liječenje neplodnosti uključuje određivanje razine AMH u serumu i tjelesne težine pacijenta.
4. Pripravak za uporabu prema bilo kojem od patentnih zahtjeva 2 ili 3 naznačen time što je za liječenje azijskog pacijenta koji ima tjelesnu težinu < 59 kg, na primjer < 56 kg, na primjer < 55 kg, na primjer < 52 kg, na primjer < 50 kg, na primjer <45 kg, na primjer < 42 kg, na primjer < 31,5 kg.
5. Pripravak za uporabu prema bilo kojem od patentnih zahtjeva 2 do 4 naznačen time što je za liječenje azijskog pacijenta koji ima AMH ≥ 16 pmol/L, na primjer AMH ≥ 19 pmol/L, na primjer AMH ≥ 26 pmol/L, na primjer AMH ≥ 28 pmol/L, na primjer AMH ≥ 30 pmol/L, na primjer AMH ≥ 40 pmol/L.
6. Pripravak za uporabu prema bilo kojem od patentnih zahtjeva 2 do 5 naznačen time što je za liječenje azijskog pacijenta koji ima tjelesnu težinu < 52kg i AMH ≥ 26 pmol/L.
7. Pripravak za uporabu prema patentnom zahtjevu 6 naznačen time što liječenje neplodnosti uključuje korak identifikacije pacijenta na temelju razine AMH u serumu i tjelesne težine pacijenta, te korak davanja doze pacijentu koji ima AMH ≥ 26 pmol/L i tjelesnu težinu < 52kg.
8. Pripravak za upotrebu prema bilo kojem prethodnom patentnom zahtjevu naznačen time što sadrži dnevnu dozu od 6 µg rekombinantnog FSH.
9. Pripravak za upotrebu prema bilo kojem prethodnom patentnom zahtjevu naznačen time što FSH je rekombinantni FSH.
10. Pripravak za upotrebu prema bilo kojem prethodnom patentnom zahtjevu naznačen time što rekombinantni FSH uključuje α2,3- i α2,6-sijaliciju.
11. Lijek za upotrebu u liječenju neplodnosti kod azijskog (npr. japanskog) pacijenta naznačen time što sadrži rekombinantni folikulostimulacijski hormon (FSH); pri čemu se lijek daje azijskom pacijentu (npr. japanskom) za kojeg je utvrđeno da ima razinu AMH u serumu od ≥15 pmol/L i tjelesnu težinu manju od 60 kg; i pri čemu se lijek primjenjuje u dnevnoj dozi od 6 do 8 µg rekombinantnog FSH.
12. Lijek za uporabu prema patentnom zahtjevu 11, naznačen time što liječenje neplodnosti uključuje korak određivanja razine AMH u serumu i tjelesne težine pacijenta, te korak davanja doze pacijentu koji ima definiranu razinu AMH u serumu i tjelesnu težinu.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17189119 | 2017-09-01 | ||
| EP18768795.9A EP3675894B1 (en) | 2017-09-01 | 2018-08-31 | Composition for controlled ovarian stimulation |
| PCT/EP2018/073442 WO2019043143A1 (en) | 2017-09-01 | 2018-08-31 | COMPOSITION FOR CONTROLLED OVARIAN STIMULATION |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20211802T1 true HRP20211802T1 (hr) | 2022-03-04 |
Family
ID=59772482
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20211802TT HRP20211802T1 (hr) | 2017-09-01 | 2018-08-31 | Pripravak za kontroliranu stimulaciju jajnika |
Country Status (30)
| Country | Link |
|---|---|
| US (2) | US11744879B2 (hr) |
| EP (2) | EP3675894B1 (hr) |
| JP (2) | JP6856819B2 (hr) |
| KR (1) | KR20200045543A (hr) |
| CN (1) | CN111050787A (hr) |
| AR (1) | AR112541A1 (hr) |
| AU (1) | AU2018326556A1 (hr) |
| BR (1) | BR112020003379A2 (hr) |
| CA (1) | CA3073624A1 (hr) |
| CL (1) | CL2020000482A1 (hr) |
| DK (1) | DK3675894T3 (hr) |
| EA (1) | EA202090480A1 (hr) |
| ES (1) | ES2904787T3 (hr) |
| HR (1) | HRP20211802T1 (hr) |
| HU (1) | HUE056726T2 (hr) |
| IL (1) | IL272763B2 (hr) |
| JO (1) | JOP20200034A1 (hr) |
| LT (1) | LT3675894T (hr) |
| MA (2) | MA50034B1 (hr) |
| MD (1) | MD3675894T2 (hr) |
| MX (1) | MX2020002235A (hr) |
| PH (1) | PH12020500404A1 (hr) |
| PL (1) | PL3675894T3 (hr) |
| PT (1) | PT3675894T (hr) |
| RS (1) | RS62810B1 (hr) |
| SG (1) | SG11202003840QA (hr) |
| SI (1) | SI3675894T1 (hr) |
| TW (1) | TWI749255B (hr) |
| UA (1) | UA126869C2 (hr) |
| WO (1) | WO2019043143A1 (hr) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202237173A (zh) * | 2020-12-09 | 2022-10-01 | 荷蘭商菲林公司 | 用於受控的卵巢刺激之組成物及方法 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2217113T5 (es) * | 2000-01-27 | 2008-11-01 | Laboratoires Serono Sa | Uso de fsh para tratar infertilidad. |
| US20040248784A1 (en) | 2003-06-03 | 2004-12-09 | Marco Filicori | Unitary combinations of FSH and hCG |
| ES2494928T3 (es) * | 2007-09-21 | 2014-09-16 | Pharmabrand S.A. | Composición que comprende polisacáridos mucilaginosos derivados de Aloe barbadensis combinados con liposomas, procedimiento para la obtención de los mismos y su uso como protector solar, un agente antiacné, un regenerador epidérmico y un hidratante |
| TWI488640B (zh) | 2008-04-16 | 2015-06-21 | Ferring Int Ct Sa | 藥學製劑 |
| WO2011089602A2 (en) * | 2010-01-21 | 2011-07-28 | Ramot At Tel-Aviv University Ltd. | Aloe-emodin derivatives and use thereof for the treatment of cancer |
| WO2012042381A1 (en) | 2010-09-29 | 2012-04-05 | Ferring B.V. | Composition for controlled ovarian stimulation |
| EP2717904A1 (en) | 2011-06-06 | 2014-04-16 | Ferring BV | Pharmaceutical preparation comprising recombinant fsh |
| JO3092B1 (ar) * | 2011-08-08 | 2017-03-15 | Ferring Bv | مركب لتحفيز مسيطر عليه للمبيض |
| BR112016023668A2 (pt) * | 2014-04-18 | 2017-10-17 | Glycotope Gmbh | hiperestimulação ovariana controlada com hormônio de estimulação de folículo humano recombinante aperfeiçoado |
| EP4289477A3 (en) | 2015-02-26 | 2024-02-21 | Ferring B.V. | Menotropin for treating infertility |
| JP7079094B2 (ja) * | 2015-04-17 | 2022-06-01 | フェリング ベスローテン フェンノートシャップ | 不妊症の処置のための組成物 |
| CN107532172A (zh) | 2015-04-24 | 2018-01-02 | 辉凌公司 | 产生***的方法 |
| WO2016207353A1 (en) | 2015-06-26 | 2016-12-29 | Ferring B.V. | Methods of purification and/or viral inactivation |
| US20210038694A1 (en) | 2018-04-30 | 2021-02-11 | Ferring B.V. | Composition for controlled ovarian stimulation |
| KR20210079276A (ko) | 2018-10-17 | 2021-06-29 | 훼링 비.브이. | 제어된 난소 자극을 위한 조성물 및 방법 |
-
2018
- 2018-08-31 ES ES18768795T patent/ES2904787T3/es active Active
- 2018-08-31 CN CN201880055934.1A patent/CN111050787A/zh active Pending
- 2018-08-31 RS RS20220042A patent/RS62810B1/sr unknown
- 2018-08-31 PT PT187687959T patent/PT3675894T/pt unknown
- 2018-08-31 WO PCT/EP2018/073442 patent/WO2019043143A1/en unknown
- 2018-08-31 EP EP18768795.9A patent/EP3675894B1/en active Active
- 2018-08-31 AR ARP180102492 patent/AR112541A1/es unknown
- 2018-08-31 SG SG11202003840QA patent/SG11202003840QA/en unknown
- 2018-08-31 UA UAA202002175A patent/UA126869C2/uk unknown
- 2018-08-31 US US16/642,777 patent/US11744879B2/en active Active
- 2018-08-31 TW TW107130683A patent/TWI749255B/zh active
- 2018-08-31 EP EP21196378.0A patent/EP3973982A1/en active Pending
- 2018-08-31 EA EA202090480A patent/EA202090480A1/ru unknown
- 2018-08-31 MD MDE20200700T patent/MD3675894T2/ro unknown
- 2018-08-31 HU HUE18768795A patent/HUE056726T2/hu unknown
- 2018-08-31 CA CA3073624A patent/CA3073624A1/en active Pending
- 2018-08-31 MA MA50034A patent/MA50034B1/fr unknown
- 2018-08-31 MA MA056224A patent/MA56224A/fr unknown
- 2018-08-31 BR BR112020003379-0A patent/BR112020003379A2/pt unknown
- 2018-08-31 HR HRP20211802TT patent/HRP20211802T1/hr unknown
- 2018-08-31 KR KR1020207009105A patent/KR20200045543A/ko not_active Application Discontinuation
- 2018-08-31 JP JP2020512546A patent/JP6856819B2/ja active Active
- 2018-08-31 AU AU2018326556A patent/AU2018326556A1/en active Pending
- 2018-08-31 DK DK18768795.9T patent/DK3675894T3/da active
- 2018-08-31 PL PL18768795T patent/PL3675894T3/pl unknown
- 2018-08-31 LT LTEPPCT/EP2018/073442T patent/LT3675894T/lt unknown
- 2018-08-31 IL IL272763A patent/IL272763B2/en unknown
- 2018-08-31 MX MX2020002235A patent/MX2020002235A/es unknown
- 2018-08-31 JO JOP/2020/0034A patent/JOP20200034A1/ar unknown
- 2018-08-31 SI SI201830484T patent/SI3675894T1/sl unknown
-
2020
- 2020-02-27 CL CL2020000482A patent/CL2020000482A1/es unknown
- 2020-02-28 PH PH12020500404A patent/PH12020500404A1/en unknown
- 2020-10-30 JP JP2020182295A patent/JP7373479B2/ja active Active
-
2023
- 2023-07-25 US US18/226,206 patent/US20240024424A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20191437T1 (hr) | Sastav za kontroliranu stimulaciju jajnika | |
| BR112021024137A2 (pt) | Dispositivos e métodos para entrega de dose com precisão | |
| MX2023005223A (es) | Estructuras de permanencia, y metodos relacionados. | |
| BR112018005349A2 (pt) | preparação farmacêutica de anticorpo anti-pd-1 estável e sua aplicação em medicamentos | |
| MY188749A (en) | Compositions comprising a combination of nivolumab and ipilimumab | |
| EP4238597A3 (en) | The invention relates to a drug delivery device | |
| MX2022009523A (es) | Formulaciones farmaceuticas. | |
| BR112019011070A2 (pt) | regeneração óssea direcionada à fratura através da estimulação do receptor de hormônio da paratireoide | |
| BR0210630A (pt) | Sistema fornecedor de liberação prolongada | |
| BR112019008021A2 (pt) | métodos de distribuição de um polipeptídeo neuroprotetor ao sistema nervoso central | |
| HRP20211802T1 (hr) | Pripravak za kontroliranu stimulaciju jajnika | |
| NZ769954A (en) | Syringe devices for use in an emergency | |
| MX2016014346A (es) | Tratamiento de enfermedad de crohn con 6-mercaptopurina de liberacion prolongada. | |
| MX2019014666A (es) | Composicion farmaceutica que comprende un conjugado de anticuerpo contra c-met-farmaco y uso del mismo. | |
| BR112018072602A2 (pt) | composições e métodos para prover hormônio da tiroide ou análogos do mesmo | |
| JP2021046398A5 (hr) | ||
| MX2017013643A (es) | Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde particulas y una matriz. | |
| Pang et al. | The impact of dual antiplatelet therapy duration on primary composite endpoint after drug-eluting stent implantation: A meta-analysis of 10 randomized trials | |
| WO2020089942A3 (en) | A liquid injectable composition | |
| He et al. | HDL quantity and function are potential therapeutic targets for abdominal aortic aneurysm | |
| PH12018500889A1 (en) | Pharmaceutical preparation for delivery of porous material to large intestine or lower part of small intestine | |
| MX2020006886A (es) | Sistema para suministro de medicamento. | |
| Dobler | Unwarranted prescription variations for treatment of latent tuberculosis infection | |
| El-Battrawy et al. | Psychiatric disease among patients with takotsubo syndrome | |
| de Thé | Lessons taught by acute promyelocytic leukemia cure |